Abstract
1 Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois, Chicago, IL. 2 Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, IL. 3 Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium. 4 Department of Nephrology, UZ Leuven, Leuven, Belgium. Received 21 March 2023. Revision received 13 May 2023. Accepted 17 May 2023. The authors declare no conflicts of interest. W.E.F. participated in data collection, analysis, and writing of the article. M.N. participated in the writing of the article. W.E.F. is a board member for Tutela Pharmaceuticals, Inc., a 501(c)(3) nonprofit, and CTI Clinical Trial Services and is a consultant for Transplant Therapeutics Consortium, Critical Path Institute, and TRACT Therapeutics, Inc. Correspondence: William E. Fitzsimmons, PharmD, MS, University of Illinois, College of Pharmacy, 833 S Wood St, Chicago, IL 60607. ([email protected]).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
